Advertisement
Dr. Poste is Chief Scientist of the Complex Adaptive Systems Initiativeand Director of The Biodesign Institute at Arizona State University. Theresearch programs led by Dr. Poste combine research in biotechnology,nanotechnology, materials science and advanced computing. He also serves asChief Executive of Health Technology Networks, a consulting firm thatspecializes in the application of genomic technologies and computing inhealthcare. From 1992 to 1999, he was Chief Science and Technology Officer andpresident of Research & Development for SmithKline Beecham, where he oversawthe registration of 31 drug, vaccine and diagnostic products. Dr. Poste is aFellow of the Royal College of Pathologists, a Fellow of the Royal Society andthe UK Academy of Medicine, a Distinguished Fellow at the Hoover Institutionof Stanford University and a member of the Council for Foreign Relations.
Advertisement
"George has been an invaluable asset to Caris since he first joined ourBoard in 2006. We look forward to getting the benefit of the additionalcontributions that George now will be able to offer in his more active rolewithin our companies," said David D. Halbert, Chairman of CDX Holdings. "Hisunderstanding and foresight in diagnostics and personalized medicine istremendous. He was instrumental in formulating our strategy that brought usinto molecular diagnostics with our acquisition of Molecular Profiling, Inc.,now called Caris MPI and the key subsidiary of CMDx, at the beginning of theyear."
Dr. Poste has published over 350 scientific papers and co-edited 14 bookson cancer, drug delivery and health policy. In 2004 he was named "R&DScientist of the Year" by R&D Magazine and in 2006 he received the Einsteinaward from the Global Business Leadership Council. He previously served aschairman of the task force on bioterrorism for the U.S. Department of Defense.He serves as a member of the Defense Science Board of the Department ofDefense and the Institute of Medicine Board of Global Health.
"I am honored to have the opportunity to work more closely with thedistinguished team David has assembled at Caris Dx and Caris MPI," commentedDr. Poste. "I have appreciated the interactions I have experienced with thegroup in the past two years in forging the union of anatomic pathology andmolecular diagnostics. I look forward to influencing and driving thecompanies' mission to accelerate the delivery of the highest qualitypersonalized medicine into the marketplace to improve patient care and theefficient use of healthcare resources."
About CDX Holdings
CDX Holdings is the parent company of Caris Diagnostics and CarisMolecular Diagnostics, whose principal subsidiary is Caris MPI. Through itssubsidiaries, CDX Holdings is a leading provider of the highest qualitydiagnostic, translational development and pharmaceutical servicesencompassing anatomic pathology and molecular testing. Formed in 1996, thecompany is headquartered in Irving, Texas, operates four laboratories: Irving,Texas; Phoenix, Arizona (2 sites); and Newton, Massachusetts, and providesservices to well over 2,000 physicians nationally.
Caris Diagnostics provides world-class pathology services to physicianswho treat patients in the community setting. The company providesacademic-caliber medical consults through its indu
